We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Ultra-Portable POC Molecular Diagnostics System to Instantly Detect Infectious Diseases

By LabMedica International staff writers
Posted on 02 Feb 2024

Infectious diseases pose a significant threat to human health and have a substantial economic impact globally. More...

Timely and accurate identification of pathogens is key for prompt treatment, improved patient outcomes, and halting the spread of diseases. Traditional pathogen detection methods are usually conducted in well-equipped clinical labs, relying on advanced equipment and specialized staff. Furthermore, pre-analytical steps such as lengthy transportation can skew results and extend turnaround times (TAT), hindering effective control of infectious diseases, especially in areas with limited resources. Now, a rapid RT-PCR platform being developed to provide highly accurate, rapid, and affordable diagnoses of infectious diseases at point-of-care and near-patient settings could enable immediate treatment initiation and curtail potential disease transmission.

Novel Microdevices (Baltimore, MD, US) is advancing its affordable, portable, rapid, multiplex, and user-friendly PCR testing solution for infectious diseases. This innovative technology simplifies complex scientific processes, typically carried out in high-complexity labs, into a compact device. Point-of-care diagnostics offered by the Novel Dx device allow for immediate results, enabling prompt action instead of the extended waiting times associated with traditional laboratory tests. The Novel Dx device employs Nucleic Acid Amplification Techniques (NAAT), which is the same method used in clinical reference laboratories, to detect the genetic material of pathogens.

The Novel Dx molecular testing platform utilizes polymerase chain reaction (PCR) technology in a disposable cartridge. The patient's sample is added to this cartridge, which is then inserted into the Novel Dx system. The system analyzes genetic sequences to identify diseases and detect genetic mutations that may make bacteria resistant to antibiotics. Novel Dx is capable of providing lab-quality results in less than 15 minutes, allowing patients to be tested, diagnosed, and treated all within a single visit, thus eliminating the wait for results from more complex labs. Designed for portability and weighing just four pounds, the Novel Dx diagnostic tool is battery-operated, making it especially suitable for use in low-resource settings and low-and middle-income countries (LMICs).


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.